1. Home
  2. HBIO vs BOLD Comparison

HBIO vs BOLD Comparison

Compare HBIO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

N/A

Current Price

$0.49

Market Cap

25.7M

Sector

Industrials

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$1.14

Market Cap

25.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HBIO
BOLD
Founded
1901
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
25.7M
IPO Year
2000
2024

Fundamental Metrics

Financial Performance
Metric
HBIO
BOLD
Price
$0.49
$1.14
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$2.50
$4.00
AVG Volume (30 Days)
377.0K
65.9K
Earning Date
01-01-0001
06-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$116,176,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.96
52 Week High
$0.95
$1.79

Technical Indicators

Market Signals
Indicator
HBIO
BOLD
Relative Strength Index (RSI) 33.59 46.52
Support Level $0.47 $1.10
Resistance Level $0.55 $1.20
Average True Range (ATR) 0.04 0.03
MACD -0.01 0.00
Stochastic Oscillator 6.33 25.00

Price Performance

Historical Comparison
HBIO
BOLD

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: